Loading...

Solid Biosciences ($SLDB)

Stock Image

SLDB Overview

Solid Biosciences, a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States.The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles.Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein.In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits.Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT Solid Biosciences

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.